InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| Puromycin | A parasite DNA binding protein with potential to influence disease susceptibi... | 2023 | PLoS One | Durrani Z. et al. | DOI: 10.1371/journal.pone.0286526 |
| G418 (Geneticin) | A parasite DNA binding protein with potential to influence disease susceptibi... | 2023 | PLoS One | Durrani Z. et al. | DOI: 10.1371/journal.pone.0286526 |
| Human TLR4 Reporter HEK293 Cells (NF-κB) | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections. | 2023 | mSphere | Mursalin M.H. et al. | DOI: 10.1128/msphere.00044-23 |
| HEK-Blue™ Detection | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections. | 2023 | mSphere | Mursalin M.H. et al. | DOI: 10.1128/msphere.00044-23 |
| Pam3CSK4 | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections. | 2023 | mSphere | Mursalin M.H. et al. | DOI: 10.1128/msphere.00044-23 |
| Human TLR2 Reporter HEK293 Cells (NF-κB) | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections. | 2023 | mSphere | Mursalin M.H. et al. | DOI: 10.1128/msphere.00044-23 |
| HEK-Blue™ Selection | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections. | 2023 | mSphere | Mursalin M.H. et al. | DOI: 10.1128/msphere.00044-23 |
| OxPAPC | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections. | 2023 | mSphere | Mursalin M.H. et al. | DOI: 10.1128/msphere.00044-23 |
| Normocin® - Antimicrobial Reagent | Tocilizumab suppresses NF-kappa B activation via toll-like receptor 9 signali... | 2023 | Clin Exp Immunol. | Hashimoto T. et al. | DOI: 10.1093/cei/uxad064 |
| Zeocin® | Tocilizumab suppresses NF-kappa B activation via toll-like receptor 9 signali... | 2023 | Clin Exp Immunol. | Hashimoto T. et al. | DOI: 10.1093/cei/uxad064 |
| Blasticidin | Tocilizumab suppresses NF-kappa B activation via toll-like receptor 9 signali... | 2023 | Clin Exp Immunol. | Hashimoto T. et al. | DOI: 10.1093/cei/uxad064 |
| Human TLR9 Reporter HEK293 Cells (NF-κB) | Tocilizumab suppresses NF-kappa B activation via toll-like receptor 9 signali... | 2023 | Clin Exp Immunol. | Hashimoto T. et al. | DOI: 10.1093/cei/uxad064 |
| Plasmocin® - Mycoplasma Elimination Reagent | Soluble monomeric human programmed cell death-ligand 1 inhibits the functions... | 2023 | Front Immunol. | Liang Z. et al. | DOI: 10.3389/fimmu.2023.1133883 |
| Puromycin | Kremen2 drives the progression of non-small cell lung cancer by preventing SO... | 2023 | J Exp Clin Cancer Res. | Sun Y. et al. | DOI: 10.1186/s13046-023-02692-3 |
| STING inhibitor | Role of the cGAS/STING pathway in the control of Brucella abortus infection a... | 2023 | Front Immunol. | Alonso Paiva I.M. et al. | DOI: 10.3389/fimmu.2023.1116811 |
| Imiquimod (R837) | Activation of TLR7-mediated autophagy increases epileptic susceptibility via ... | 2023 | Exp Mol Med. | Liu J. et al. | DOI: 10.1038/s12276-023-01000-5 |
| 293XL/TLR7 | Engineered tRNAs suppress nonsense mutations in cells and in vivo. | 2023 | Nature | Albers S. et al. | DOI: 10.1038/s41586-023-06133-1 |
| 293XL/TLR8 | Engineered tRNAs suppress nonsense mutations in cells and in vivo. | 2023 | Nature | Albers S. et al. | DOI: 10.1038/s41586-023-06133-1 |
| Imiquimod (R837) | Prolonged inflammatory resolution in allergic asthma relates to dysfunctional... | 2023 | Ann Allergy Asthma Immunol. | Ekstedt S. et al. | DOI: 10.1016/j.anai.2023.05.030 |
| QUANTI-Blue™ | Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients wit... | 2023 | J Interferon Cytokine Res. | Vanker M. et al. | DOI: 10.1089/jir.2023.0003 |